Objective: The ReSTAGE collaboration evaluated four menstrual markers of entry to late-stage menopausal transition. The aim of this study was to assess the additional usefulness of Bpersistence[ in relation to a clinically accessible menstrual marker of late menopausal transition, taking age into account.
R eSTAGE 1,2 is a multistudy 3<6 collaboration that draws together information provided by longitudinal studies of midlife women that have incorporated the collection of menstrual calendars.
ReSTAGE has used the menstrual calendar evidence provided by these studies to evaluate several menstrual Bmarkers[ of the menopausal transition proposed in 2001 by the Stages of Reproductive Aging Workshop. 2, 7 Markers are defined in terms of the intervals between consecutive dates of onset of menstrual bleeding (Bsegments[). An interval of at least 90 days is currently recognized as a marker of the late menopausal transition. 8 ReSTAGE recommended that the 60-day interval proposed by the Stages of Reproductive Aging Workshop be used instead of the 90-day interval as a marker of the beginning of late-stage transition. 1 Two other menstrual markers of entry to late-stage transition considered by ReSTAGE required knowledge of a history of at least 10 of a woman's immediately preceding segments, making them much less accessible in a clinical situation than the single segmentYdependent 60-and 90-day markers. These other markers (running range more than 42 days and Bskipped segment[) often occurred on the same segment as the 60-day marker, and their distributions of age at first occurrence after a woman had reached age 40 years were very similar to that of the 60-day marker. Among women whose final menstrual period (FMP) was observed in the four studies, 92% to 100% had experienced the 60-day marker after age 40 years. The corresponding percentages were very similar for the running range and skipped segment markers, but they were somewhat lower (79%-91%) for the 90-day marker.
In the context of considering markers of entry to early menopausal transition, ReSTAGE made use of the concept of the Bpersistence[ of a menstrual marker. 4, 9 A marker is said to occur persistently, or Bwith persistence,[ if it recurs within the next 10 bleeding segments after its initial occurrence. In this article, we consider whether the concept of persistence can be useful in a clinical context in relation to the late-stage 60-day marker, taking into account whether the woman is younger than 45 years.
METHODS
This analysis is based on menstrual calendar data recorded by women from a minimum age of 35 years in the TREMIN (735 women) and Seattle Midlife Women's Health Study (SMWHS; 279 women) studies.
The institutional review boards at the Universities of Michigan and Washington approved the secondary analyses by ReSTAGE of the data from the TREMIN and SMWHS studies.
Detailed information comparing the scope and design of these population-based prospective studies is available elsewhere. 1, 9, 10 Women in both studies completed yearly menstrual calendar cards.
A bleeding segment is defined, according to World Health Organization recommendations, 11 as a bleeding episode followed by a bleeding-free interval. ReSTAGE defined a bleeding-free interval as consisting of at least 3 days, so that gaps of 1 or 2 days between bleeding days are regarded as part of the same bleeding episode, which must consist of at least 1 day. Segments associated with pregnancies and the first three segments after a birth or abortion are excluded from the analyses, as are segments associated with the use of hormone therapy or hormonal contraception.
The age at which a marker occurs is the woman's age on the day beginning the segment at which the marker event is first observed for the woman, after the age of 40 years. If the marker event recurs within the 10 segments following this day, the age at persistence of the marker concurs with the age at the marker.
Results are stated in terms of time from marker to FMP (verified retrospectively by 12 mo of subsequent amenorrhea), which was observed in the menstrual calendars of 211 (29%) women in the TREMIN study and for 52 (19%) women in the SMWHS study. Kaplan-Meier estimates of age at FMP were generated for those women whose FMP was not observed in their calendar data. The time between the first occurrence of a marker and FMP is calculated as the difference between her age, or estimated age, at FMP and her age at the occurrence of the marker. Table 1 shows, for the 60-and 90-day markers, the classification of women older than 40 years in the two studies into those for whom the marker was not observed, those for whom it was observed or estimated to first occur within 5 years of FMP, and those for whom it was observed or estimated to first occur earlier than 5 years before FMP. The percentages for the marker without and with recurrence in the next 10 segments (Bpersistence[) are contrasted.
RESULTS
One in eight women does not experience the 90-day marker, whereas only 1 in 25 does not experience the 60-day marker. Approximately equal proportions (94/5) of women experience both the 60-day and the 90-day markers within 5 years of their FMP. For one in seven, the first occurrence of the 60-day marker is earlier than 5 years before the FMP. This happens for only 1 in 33 women for the 90-day marker.
The more stringent requirement of persistence results in greater percentages of women not experiencing the markers, with the effect being more marked for the 90-day marker. The proportion of women experiencing the 60-day marker within 5 years of the FMP is hardly affected (still 4/5), whereas this proportion drops to only about one in two for the 90-day marker. Table 2 shows the estimates of the probability of reaching the FMP within 5 years for women older than 40 years who experience the 60-and 90-day markers with and without recurrence in the next 10 segments (persistence), grouped by the age at which they first experience the marker. Each of the markers is more likely to occur first in the age range 45 to 49 years than earlier or later.
If the 90-day marker occurs with persistence at any age beyond 40 years, or if either marker occurs first with or without persistence at age 50 years or beyond, it is almost a foregone conclusion that the FMP will occur within 5 years. However, for women first experiencing the markers between the ages of 40 and 49 years, the percentages reaching the FMP within 5 years are higher for the 90-day marker than for the 60-day marker, but fewer women experience the 90-day marker.
A similar number and percentage of women first experiencing the 90-and 60-day marker with persistence between the ages of 45 and 49 years reach their FMP within 5 years (n = 193 and 189; 94% and 93%, respectively). For women first experiencing these markers between the ages of 40 and 44 years, a higher percentage (84%) of those with the 60-day marker with persistence reach the FMP within 5 years than do those with the 90-day marker (77%), which also occurs in fewer women. Women with both of these markers have higher percentages reaching the FMP within 5 years than those the 60-day marker without persistence (61%).
DISCUSSION
Two of the studies brought together by the ReSTAGE collaboration, the TREMIN, begun in the 1930s, and the SMWHS, begun in 1990, have menstrual calendar data that allow comparison in women first experiencing menstrual markers of the menopausal transition in the age ranges from 40 to 44 years and from 45 to 49 years.
Two of the markers of the late stage of the menopausal transition assessed by ReSTAGE, 1 the accepted 90-day marker and the recommended 60-day marker, depend on information about a single bleeding segment and are thus more readily accessible in a clinical setting than are markers depending on information about a history of segments.
We have shown that the idea of persistence, or early recurrence, of a menstrual marker of a stage of the menopausal transition, first considered by ReSTAGE in relation to an early transition marker, can add to the value of the 60-day marker of late transition in a clinical setting and that the value added varies with the woman's age. Specifically, recurrence within the next 10 segments of the 60-day marker when it is first experienced between the ages of 40 and 44 years is as informative about the arrival of the FMP within 5 years as is the first experience of a single segment of 60 or more days in length between the ages of 45 and 49 years. Both these events have a probability of about 0.85, or odds of between 5 and 6 to 1.
CONCLUSIONS
The traditional 90-day marker itself performs better among women aged 45 to 49 years (94% success predicting FMP within 5 years) than among those aged 40 to 44 years (77%), but its relative rarity means that applying the idea of persistence to it gives a poor trade-off for better prediction efficiencyVthe persistent 90-day marker happens to very few women. The 60-day marker performs almost as well without as with the persistence requirement among women first experiencing it in the 45 to 49 years age range. The persistent 60-day marker has better characteristics than does the 90-day marker for women first experiencing it between the ages of 40 to 44 years.
